P. Koralewski

发表

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

C. Bokemeyer, F. D. De Braud, C. Stroh, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

C. Bokemeyer, I. Bondarenko, I. Çelik, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study.

B. Rini, C. Szczylik, B. Escudier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral vinorelbine: feasibility and safety profile.

E. Lemarié, T. Delozier, R. Ramlau, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study

C. Bokemeyer, A. Zubel, J. Aparicio, 2007 .

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.

T. Ciuleanu, B. Alekseev, S. Pal, 2022, European urology.

Patients and Methods: the European Organisation for Research and Treatment of Cancer Qol Questionnaire

C. Bokemeyer, M. Benasso, R. Hitt, 2022 .

Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study

J. Bonneterre, M. Campone, M. Błasińska-Morawiec, 2007, Cancer Chemotherapy and Pharmacology.

First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.

A. Ravaud, B. Melichar, A. Santoro, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer

T. Ciuleanu, A. Croitoru, P. Koralewski, 2020, Oncotarget.

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

C. Bokemeyer, C. Stroh, I. Çelik, 2008 .

[Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group].

K. Roszkowski, W. Olszewski, R. Ramlau, 2007, Pneumonologia i alergologia polska.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

P. Murawa, M. Gore, C. Bokemeyer, 2010, International journal of cancer.

A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

M. Buyse, R. Ramlau, E. Stoelben, 2011, The Lancet. Oncology.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bohuslav Melichar, A. Ravaud, B. Melichar, 2007, The Lancet.

Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study)

D. Cunningham, J. Bridgewater, P. Mainwaring, 2005 .

Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer

M. Campone, M. Błasińska-Morawiec, P. Koralewski, 2009, Cancer Chemotherapy and Pharmacology.

Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).

D. Miles, J. O’Shaughnessy, V. Diéras, 2009 .

T. Ciuleanu, B. Alekseev, S. Pal, 2022, The oncologist.

6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study

C. Bokemeyer, I. Çelik, A. Zubel, 2009 .

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

A. Ravaud, M. Fishman, R. Ramlau, 2012, Cancer.

4518 POSTER First-line bevacizumab improves progression-free survival with lower doses of interferon-a2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN)

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

J. Robertson, M. Krzakowski, J. Bonneterre, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

R. Ferris, A. Argiris, R. Haddad, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

R. Ferris, A. Argiris, U. Müller-Richter, 2021, Annals of Oncology.

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

A. Schueler, R. Knecht, R. Hitt, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine as adjuvant treatment for stage III colon cancer.

Markus Abt, Joseph McKendrick, Marek Pawlicki, 2005, The New England journal of medicine.

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.

José Miguel Reyes, Jean-Yves Douillard, Michael Lahn, 2006, Journal of Clinical Oncology.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

W. Scheithauer, J. Zaluski, H. Burris, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study

M. Gore, S. Parsons, A. Burges, 2007 .

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.

X. Pivot, J. Lotz, A. Chan, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter phase II study of XRP 6258 administered as a 1h i . v . infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

X. Pivot, J. Lotz, A. Chan, 2008 .

Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining.

J. Tabernero, P. Ruff, D. Cunningham, 2010 .

120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study

L. Livi, T. Mekhail, T. Csoszi, 2021, Annals of Oncology.

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

C. Bokemeyer, A. Zubel, E. Starosławska, 2007 .

Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study.

J. Baselga, R. Knecht, R. Hitt, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC)

D. Amadori, H. Sommer, P. Koralewski, 2001 .

Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.

W. Miller, D. Haller, G. Bodoky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

C. Porta, M. Atkins, B. Rini, 2017 .

Pharmacokinetics and Toxicity of Oral (-)-(S)-Bromofosfamide in Lung Cancer Patients

P. Koralewski, M. Kobylińska, K. Kobylińska, 2001, Arzneimittelforschung.

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.

J. Zaluski, D. Cunningham, J. Bridgewater, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of ITS fentanyl given directly after tramadol to patients withcancer related pain (based on FEN-POL-2 trial)

R. Ramlau, M. Krzakowski, J. Zaluski, 2002 .

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study

P. Murawa, S. Parsons, P. Koralewski, 2008 .

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

C. Bokemeyer, F. D. De Braud, C. Stroh, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness of cyproheptadine in the management of delayed vomiting after cisplatin-based chemotherapy and the assessment of the influence of cyproheptadine on ąuality of life

W. Cegielski, P. Koralewski, L. Nawara, 2000 .

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

M. Lena, F. Peradotto, P. Koralewski, 2007 .